These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 2936201)

  • 1. Platelet-activating factor: a unique lipid chemical mediator.
    Hanahan DJ; Buxton D; Halvorsen O; Olson MS
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():707-9. PubMed ID: 2936201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of beta-adrenergic stimulation on 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine-mediated vasoconstriction and glycogenolysis in the perfused rat liver.
    Fisher RA; Kumar R; Hanahan DJ; Olson MS
    J Biol Chem; 1986 Jul; 261(19):8817-23. PubMed ID: 3013865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-activating factor-mediated vasoconstriction and glycogenolysis in the perfused rat liver.
    Buxton DB; Fisher RA; Hanahan DJ; Olson MS
    J Biol Chem; 1986 Jan; 261(2):644-9. PubMed ID: 3001074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-activating factor-stimulated hepatic glycogenolysis is not mediated through cyclooxygenase-derived metabolites of arachidonic acid.
    Lapointe DS; Olson MS
    J Biol Chem; 1989 Jul; 264(21):12130-3. PubMed ID: 2501299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific antagonists of platelet activating factor-mediated vasoconstriction and glycogenolysis in the perfused rat liver.
    Buxton DB; Hanahan DJ; Olson MS
    Biochem Pharmacol; 1986 Mar; 35(6):893-7. PubMed ID: 3754140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet-activating factor and bacteremia-induced pulmonary hypertension.
    Clavijo LC; Carter MB; Matheson PJ; Wills-Frank LA; Wilson MA; Wead WB; Garrison RN
    J Surg Res; 2000 Feb; 88(2):173-80. PubMed ID: 10644485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-activating factor contributes to postischemic vasospasm.
    Wang WZ; Guo SZ; Tsai TM; Anderson GL; Miller FN
    J Surg Res; 2000 Apr; 89(2):139-46. PubMed ID: 10729242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is mannitol effective against platelet-activating factor (PAF)-induced liver damage in obstructive jaundice?
    Coker A; Coker I; Huseyinov A; Sokmen S; Karademir S
    Hepatogastroenterology; 2001; 48(40):1134-7. PubMed ID: 11490817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis.
    Shukla SD; Buxton DB; Olson MS; Hanahan DJ
    J Biol Chem; 1983 Sep; 258(17):10212-4. PubMed ID: 6309795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-activating factor in septic shock.
    Koltai M; Hosford D; Braquet PG
    New Horiz; 1993 Feb; 1(1):87-95. PubMed ID: 7922397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys.
    Patterson R; Harris KE
    J Lab Clin Med; 1983 Dec; 102(6):933-8. PubMed ID: 6644157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues.
    Humphrey DM; McManus LM; Satouchi K; Hanahan DJ; Pinckard RN
    Lab Invest; 1982 Apr; 46(4):422-7. PubMed ID: 7070056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontogeny of the responsiveness to intravenous platelet-activating factor.
    Angle MJ; Pinckard RN; Showell HJ; McManus LM
    Lab Invest; 1987 Sep; 57(3):321-8. PubMed ID: 3626521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide mediates the inhibitory action of platelet-activating factor on angiotensin II-induced renal vasoconstriction, in vivo.
    Handa RK; Strandhoy JW
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1486-91. PubMed ID: 8667214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine.
    Humphrey DM; McManus LM; Hanahan DJ; Pinckard RN
    Lab Invest; 1984 Jan; 50(1):16-25. PubMed ID: 6694349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-activating factor and shock.
    Feuerstein G; Siren AL
    Prog Biochem Pharmacol; 1988; 22():181-90. PubMed ID: 3043432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-activating factor is involved in the regulation of pathological leukocyte adhesion after liver transplantation.
    Walcher F; Marzi I; Fischer R; Bauer M; Larsen R
    J Surg Res; 1996 Feb; 61(1):244-9. PubMed ID: 8769973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-activating factor and cytokine production in the perfused rat liver.
    Denizot Y; Nathan N
    Eur Cytokine Netw; 1994; 5(3):261-2. PubMed ID: 7948762
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor).
    Shaw JO; Pinckard RN; Ferrigni KS; McManus LM; Hanahan DJ
    J Immunol; 1981 Sep; 127(3):1250-5. PubMed ID: 6267133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical evidence of platelet-activating factor (PAF) in human middle ear effusions.
    Furukawa M; Kubo N; Yamashita T
    Laryngoscope; 1995 Feb; 105(2):188-91. PubMed ID: 8544602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.